4th Quarter - Report

ALEXION PHARMACEUTICALS, INC. for ALEXION PHARMACEUTICALS, INC.

Firm
Client
Income
—
Expenses
$331,555
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Corporate tax reform Orphan Drug Tax Credit Expiring tax provisions Patent Box

LobbyistCovered position, as disclosed
LEIGH OWANO New —
VANESSA PROCTER —

Contacted: U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; SENATE

Trade (domestic/foreign) TRD

TTP TTIP TPA

LobbyistCovered position, as disclosed
GREGORY KALBAUGH —
HEIDI L WAGNER —

Contacted: U.S. Trade Representative (USTR); SENATE; HOUSE OF REPRESENTATIVES

Medicare/Medicaid MMM

CMS Part B DEMO CMMI Medicaid Reform; Texas Medicaid Medicare Hospital Inpatient Payment Reform

LobbyistCovered position, as disclosed
LEIGH OWANO New —
VANESSA PROCTER —
HEIDI L WAGNER —

Contacted: SENATE; U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES

Health Issues HCR

Drug Pricing Creates ACT (REMs) CURES Advancing Hope Act (PRV Reauthorization) ACA Implementation Issues PDUFA

LobbyistCovered position, as disclosed
LEIGH OWANO New —
VANESSA PROCTER —
HEIDI L WAGNER —

Contacted: U.S. Trade Representative (USTR); SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.